NCT02833909

Brief Summary

The objective is to investigate ex vivo the inflammatory response in hidradenitis suppurativa (HS) (activation of an inflammasome, role of pro-inflammatory cytokines) in the skin of patients treated surgically for this disease. The investigators hypothesize that Th17-derived cytokines, especially Interleukin (IL) IL-17, could serve as a relay in the inflammatory process leading to HS severity and recurrences.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2015

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2016

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 4, 2016

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 14, 2016

Completed
Last Updated

January 21, 2026

Status Verified

July 1, 2016

Enrollment Period

1 year

First QC Date

July 4, 2016

Last Update Submit

January 19, 2026

Conditions

Hidradenitis Suppurativa

Outcome Measures

Primary Outcomes (7)

  • cytokine quantification (IL1-β) by ELISA

    up to 4 days

  • cytokine quantification (IL-10) by ELISA

    up to 4 days

  • cytokines quantification (IL-13) by ELISA

    up to 4 days

  • cytokines quantification (IL-18) by ELISA

    up to 4 days

  • cytokines quantification (CXCL10) by ELISA

    up to 4 days

  • cytokines quantification (TNFα) by ELISA

    up to 4 days

  • cytokines quantification (TGFβ) by ELISA

    up to 4 days

Study Arms (2)

HS

EXPERIMENTAL
Other: surgery

Controls

EXPERIMENTAL
Other: surgery

Interventions

surgeryOTHER
ControlsHS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with moderate to severe HS in the Dermatology department of Reims CHU, and eligible for surgery
  • Patients accepting to participate to the study (signed consent)
  • Patients affiliated to a certain social scheme
  • Controls with plastic surgery but without HS, affiliated to a certain social scheme and accepting to participate

You may not qualify if:

  • Patients \<18yo

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chu Reims

France, Reims, 51092, France

Location

Related Publications (1)

  • Sanchez J, Le Jan S, Muller C, Francois C, Renard Y, Durlach A, Bernard P, Reguiai Z, Antonicelli F. Matrix remodelling and MMP expression/activation are associated with hidradenitis suppurativa skin inflammation. Exp Dermatol. 2019 May;28(5):593-600. doi: 10.1111/exd.13919.

    PMID: 30903721BACKGROUND

MeSH Terms

Conditions

Hidradenitis Suppurativa

Interventions

Surgical Procedures, Operative

Condition Hierarchy (Ancestors)

Skin Diseases, BacterialBacterial InfectionsBacterial Infections and MycosesInfectionsSkin Diseases, InfectiousSuppurationSkin DiseasesSkin and Connective Tissue DiseasesHidradenitisSweat Gland Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 4, 2016

First Posted

July 14, 2016

Study Start

March 1, 2015

Primary Completion

March 1, 2016

Study Completion

March 1, 2016

Last Updated

January 21, 2026

Record last verified: 2016-07

Locations

FR(1)